| Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study CK Chin, KJ Lim, K Lewis, P Jain, Y Qing, L Feng, CY Cheah, JF Seymour, ... British Journal of Haematology 191 (5), 806-815, 2020 | 8 | 2020 |
| Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia ER Thompson, KJC Lim, JA Kuzich, M McBean, D Westerman, CS Tam, ... Leukemia & Lymphoma 61 (8), 2024-2026, 2020 | 8 | 2020 |
| Zanubrutinib for the treatment of Waldenström Macroglobulinemia KJC Lim, CS Tam Expert Review of Hematology 13 (12), 1303-1310, 2020 | 6 | 2020 |
| Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance KJC Lim, P Di Ciaccio, MN Polizzotto, S Milliken, T Cochrane, Z Goh, ... British Journal of Haematology 201 (5), 865-873, 2023 | 4 | 2023 |
| Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’experience from Western Australia JA Kuzich, AP Hutchison, KJC Lim, P Smallbone, K Denning, MP Wright, ... Leukemia & Lymphoma 60 (14), 3417-3425, 2019 | 3 | 2019 |
| An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia KJC Lim, CS Tam Expert Opinion on Pharmacotherapy 21 (13), 1555-1564, 2020 | 2 | 2020 |
| Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related … KJC Lim, C Wellard, E Moore, S Ninkovic, WJ Chng, A Spencer, P Mollee, ... Blood 142, 3325, 2023 | 1 | 2023 |
| P-051: Inferior outcomes for Multiple Myeloma (MM) patients (pts) harbouring t (11; 14) and the promise of venetoclax, real-world Australian retrospective K Lim, D Talaulikar, J Tan, J Loh, P Puvanakumar, J Kuzich, M Ho, ... Clinical Lymphoma Myeloma and Leukemia 21, S66, 2021 | 1 | 2021 |
| Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma? KJC Lim, R Filshie The Lancet Haematology 10 (12), e942-e943, 2023 | | 2023 |
| The Role of Intravenous Immunoglobulin (IVIG) in Reducing Infection Risk in Multiple Myeloma (MM) Patients Receiving Immune-Based Therapies: A Single Center Experience KJC Lim, H Quach Blood 142, 6671, 2023 | | 2023 |
| The prognostic impact of t (11; 14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related … KJC Lim, C Wellard, D Talaulikar, JLC Tan, J Loh, P Puvanakumar, ... EJHaem 4 (3), 639-646, 2023 | | 2023 |
| The role of cytogenetics in the diagnosis of myelodysplastic syndromes (MDS) where dysplastic changes on morphology are insufficient according to WHO criteria KJC Lim, H Pertile, M Cole-Sinclair, K Dunn, S Ninkovic Pathology 54, S75, 2022 | | 2022 |
| Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study KJC Lim, P Di Ciaccio, N Hamad, MN Polizzotto, S Milliken, T Cochrane, ... Blood 138, 1456, 2021 | | 2021 |
| Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian … M Harwood, G Hodges, X Tan, CY Cheah, K Lim, M Ku, C Tam, I Lagerlof, ... Leukemia & Lymphoma 61 (14), 3412-3416, 2020 | | 2020 |
| Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study JA Kuzich, AP Hutchison, K Lim, MPF Wright, G Cull, MF Leahy, ... Blood 130, 1524, 2017 | | 2017 |
| Efficacy and Strategies to Improve Immunogenicity of Flu Vaccine in Patients with Solid Organ Malignancy on Chemotherapy Y Tomita, KJC Lim, M Cain, K Jasas Annals of Oncology 25, v107, 2014 | | 2014 |
| BAY 2416964 induces AHR-controlled gene CYP1A1 expression with IC50 of four. 30 nM inside a human monocytic U937 cells. Menu KJC Lim, CS Tam | | |
